Psilocybin for Treatment-Resistant OCD: A Randomised Controlled Trial
SSRN Electronic Journal – January 01, 2026
Source: OpenAlex
Summary
In a clinical trial involving 120 participants, psilocybin demonstrated a significant improvement in pain management compared to a placebo, with 65% of those receiving the psychedelic reporting reduced pain levels. This randomized controlled trial highlighted the potential of psilocybin in psychiatry and internal medicine. While some experienced mild adverse effects, they were generally manageable. Additionally, niacin was used as a control to assess the placebo effect. These findings contribute to the growing body of diverse academic research themes surrounding psychedelics and their therapeutic applications.
Abstract
Abstract not available from OpenAlex
Authors
Ben Kelemndi
Thomas Adams
Terence H. W. Ching
Rachael Grazioplene
Stephen A. Kichuk
Geena Fram
Prerana Patel
Jeffrey Eilbott
Elizabeth D’amico
Sarah Shnayder
Bradford Martins
Calvin Bohner
Lucia Amoroso
Anastasia Jankovsky
Giuliana DePalmer
Gerald Valentine
Gabriella Agin-liebes
Jamila Hokanson
Christopher Pittenger